Phase 1

Exp Date


Amp Volatility Score

Catalyst Info & Data Links

Potential Catalyst Events

  • TBA

From 2019 10K: "as well as our oral dual PAK4/NAMPT inhibitor, KPT-9274. ... We began clinical testing of KPT-9274 in patients with hematologic or solid tumors during 2016 and we plan to study its combination with an anti-PD1 monoclonal antibody in a phase 1 clinical study in the near future"

HC updated 5/22/20

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

KPTI's Q2 XPOVIO Net Sales...

KPTI announced their Q2 2020 XPOVIO net product sales of $18.6 Million. See AmpCard for more details. #KPTI, #XPOVIO, #SELINEXOR, #Multiple_myeloma, #STORM...

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

KPTI's Upcoming ASCO Presentat...

We invest in KPTI because they have an enterprise value below $2 billion, and an approved oral blood cancer drug, XPOVIO (Selinexor), with a new mechanism of action and blockbuster potential. XPOVIO i...

KPTI dilution event not a surp...

After reporting positive top-line Phase 3 results today, KTPI announced a follow-on offering. I provide more details about why this is not surprising as a comment to my Amp educational video to follow...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon